Volume 148, Issue 1, Pages (January 2018)

Slides:

Advertisements

Similar presentations

TYPE-SPECIFIC HUMAN PAPILLOMAVIRUS IN ENDOCERVIX, VAGINA, AND PERINEUM; IMPLICATIONS FOR VAGINAL SELF- COLLECTION Robert G. Pretorius, MD, Jerome L. Belinson,

Advertisements

Cervical Cancer: Experiences from a Cohort of HIV-infected Women Pascoe M, Magure T, Mudhokwani P et al Abstract: MOAB0202.

Date of download: 6/26/2016 From: Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in.

Regional variation in histopathology-specific incidence of invasive cervical cancer among Peruvian women Christine M. Pierce Campbell, Maria P. Curado,

Performance of mRNA- and DNA-based high-risk human papillomavirus assays in detection of high-grade cervical lesions ELINA VIRTANEN1, ILKKA KALLIALA2,3,

Volume 144, Issue 1, Pages (January 2017)

Can HPV vaccine have other health benefits more than cancer prevention

Volume 141, Issue 2, Pages (May 2016)

Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment.

Colposcopy triage. Satisfactory colposcopy is defined as complete visualization of the squamocolumnar epithelium, which comprises the cervical region most.

Status of clinical research in China

M. Arbyn, P. J. F. Snijders, C. J. L. M. Meijer, J. Berkhof, K

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.

Vaginal self-sampling is an adequate means of screening HR-HPV types in women not participating in regular cervical cancer screening C. Tamalet, L. Le.

Volume 62, Issue 6, Pages (December 2012)

Volume 60, Issue 5, Pages (November 2011)

QUIZ QUESTIONS 1) WHAT ARE THE TWO TYPES OF CERVICAL CANCER?

Prognostic value of human papillomavirus types 16 and 18 DNA physical status in cervical intraepithelial neoplasia A. Gradíssimo Oliveira, C. Delgado,

Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study Alejandra Castanon, MD, Rebecca Landy, PhD,

The Lancet Public Health

Volume 149, Issue 3, Pages (June 2018)

Prognostic value of human papillomavirus types 16 and 18 DNA physical status in cervical intraepithelial neoplasia A. Gradíssimo Oliveira, C. Delgado,

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Etiologic features of newly diagnosed epilepsy: Hospital-based study of 892 consecutive patients in West China Yang Si, Ling Liu, Jia Hu, Jie Mu, Jia-jia.

Economic evaluation of vaccination: capturing the full benefits, with an application to human papillomavirus T. Bärnighausen, D.E. Bloom, E.T. Cafiero,

Volume 69, Issue 1, Pages (January 2016)

SC17.02 Lung Cancer in China: Challenges and Perspectives

The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional.

Volume 148, Issue 1, Pages (January 2018)

The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional.

Are patients willing to travel for better ovarian cancer care?

Volume 148, Issue 1, Pages (January 2018)

Volume 71, Issue 6, Pages (June 2017)

Prevalence and treatment gap of active convulsive epilepsy: A large community-based survey in rural West China Jia Hu, Yang Si, Dong Zhou, Jie Mu, Juan.

Volume 5, Issue 1, Pages e45-e58 (January 2018)

Volume 145, Issue 2, Pages (May 2017)

Vulvar intraepithelial neoplasia: Risk factors for recurrence

Volume 144, Issue 2, Pages (February 2017)

Detection of TERC Amplification in Cervical Epithelial Cells for the Diagnosis of High- Grade Cervical Lesions and Invasive Cancer Jing Jiang, Li-Hui.

Volume 151, Issue 1, Pages (October 2018)

Wilberto Nieves-Neira, J. Julie Kim, Daniela Matei

Volume 136, Issue 2, Pages (February 2015)

Volume 152, Issue 1, Pages (January 2019)

Volume 148, Issue 1, Pages (January 2018)

Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment.

Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer E.N. Prendergast,

K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani

Volume 152, Issue 1, Pages (January 2019)

Comparing the health and economic impacts of cervical cancer screening strategies using the Cancer Risk Management Model (CRMM) C. Popadiuk, A.J. Coldman,

Volume 152, Issue 1, Pages (January 2019)

Volume 152, Issue 1, Pages (January 2019)

HPV vaccines – A review of the first decade

Cervical excisional treatment of young women: A population-based study

SH-sheikhhasani Gyn-oncologist

Volume 142, Issue 2, Pages (August 2016)

Annika Idahl, Andrea Hermansson, Ann Lalos Gynecologic Oncology

Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis Chunqing Lin,

Volume 152, Issue 1, Pages (January 2019)

Gynecologic Care for Women With HIV Infection

Volume 153, Issue 1, Pages (April 2019)

Programmatic human papillomavirus testing in cervical cancer prevention in the Jujuy Demonstration Project in Argentina: a population-based, before-and-after.

The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled.

Volume 152, Issue 1, Pages (January 2019)

Volume 152, Issue 1, Pages (January 2019)

Volume 115, Issue 1, Pages (October 2009)

Volume 153, Issue 3, Pages (June 2019)

Fig. 3. The examinations consumed by the three cervical screening strategies to detect CIN2+/CIN3+. (A) The cases of CIN2+ detected by three current cervical.

Fig. 2. Three cervical screening strategies to detect CIN2+/CIN3+

Fig. 1. Flowchart of inclusion and exclusion criteria of the study population.ASC-US, atypical squamous cells of undetermined significance; CIN, cervical.

Volume 154, Issue 1, Pages (July 2019)

Presentation transcript:

Volume 148, Issue 1, Pages 103-110 (January 2018) Human papillomavirus viral load as a useful triage tool for non-16/18 high-risk human papillomavirus positive women: A prospective screening cohort study Li Dong, Margaret Z. Wang, Xue-lian Zhao, Rui-mei Feng, Shang-ying Hu, Qian Zhang, Jennifer S. Smith, You-lin Qiao, Fang-hui Zhao Gynecologic Oncology Volume 148, Issue 1, Pages 103-110 (January 2018) DOI: 10.1016/j.ygyno.2017.11.016 Copyright © 2017 Elsevier Inc. Terms and Conditions

Fig. 1 Flowchart of the Shanxi Province Cervical Cancer Screening Study, China, 1999–2014 Abbreviation: HC2=Hybrid Capture 2; LBC=Liquid-based cytology; VIA=Visual inspection with acetic acid; HPV=Human papillomavirus; CIN2+= Cervical intraepithelial neoplasia grade 2 or worse; AC=Analytic cohort; FU=Follow-up. Gynecologic Oncology 2018 148, 103-110DOI: (10.1016/j.ygyno.2017.11.016) Copyright © 2017 Elsevier Inc. Terms and Conditions

Fig. 2 Ten-year cumulative incidence rate of cervical intraepithelial neoplasia grade 2 or worse in 209 hrHPV-positive women, stratified by type-specific hrHPV viral loads at AC baseline Abbreviation: AC=Analytic cohort; HPV=Human papillomavirus; hrHPV=High-risk HPV; CIR=Cumulative incidence rate; CIN2+= Cervical intraepithelial neoplasia grade 2 or worse; HR=Hazard ratio; CI=Confidence interval; non-HPV16= Agroup of species 9 oncogenic types other than HPV16, non-HPV18=A group of species 7 oncogenic types other than HPV18. Note: ⁎ Women concurrently infected with HPV 16 were not included in the analysis. † HPV viral load was categorized by RLU/CO ratio: Low=1–9.99 RLU/CO; Moderate=10–99.99 RLU/CO; High=100 or higher RLU/CO; ‡ Moderate viral load was taken as the reference to evaluate the HR of high viral load. The x-axis is logarithmic. Gynecologic Oncology 2018 148, 103-110DOI: (10.1016/j.ygyno.2017.11.016) Copyright © 2017 Elsevier Inc. Terms and Conditions

Fig. 3 Ten-year cumulative incidence rate of cervical intraepithelial neoplasia grade 2 or worse in 209 hrHPV-positive women, stratified by triage methods according to HPV16/18 infection status at AC baseline Abbreviation: HPV=Human papillomavirus; hrHPV=Human-risk HPV; AC=Analytic cohort; CIR=Cumulative incidence rate; CIN2+=Cervical intraepithelial neoplasia grade 2 or worse; CI=Confidence interval; HR=Hazard ratio; NILM=Negative for intraepithelial lesion or malignancy; VIA=Visual inspection with acetic acid; Note: The x-axis is logarithmic. Gynecologic Oncology 2018 148, 103-110DOI: (10.1016/j.ygyno.2017.11.016) Copyright © 2017 Elsevier Inc. Terms and Conditions